| scholarly article | Q13442814 |
| P2093 | author name string | Yusuke Nakamura | |
| Yosuke Harada | |||
| Yo Matsuo | |||
| Takashi Miyamoto | |||
| Naofumi Takamatsu | |||
| Suyoun Chung | |||
| Kyoko Kijima | |||
| Akiko Taira | |||
| Aiko Kudo | |||
| Yoshiko Fujisawa | |||
| P2860 | cites work | Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family | Q21195232 |
| A novel src homology 3 domain-containing adaptor protein, HIP-55, that interacts with hematopoietic progenitor kinase 1 | Q22010811 | ||
| Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities | Q27026425 | ||
| ONCOMINE: a cancer microarray database and integrated data-mining platform | Q28255103 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer | Q29619481 | ||
| DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis | Q30458737 | ||
| Biology-driven cancer drug development: back to the future | Q33552888 | ||
| Pancreatic cancer: molecular pathogenesis and new therapeutic targets | Q33899954 | ||
| Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway | Q33960305 | ||
| Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer | Q34530885 | ||
| Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis | Q34621899 | ||
| Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. | Q35068076 | ||
| EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner | Q35075212 | ||
| Isolation of p53-target genes and their functional analysis | Q35628056 | ||
| MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells | Q36275700 | ||
| MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. | Q37098261 | ||
| Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells | Q37099799 | ||
| Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer | Q37360234 | ||
| Integrated genomic and epigenomic analysis of breast cancer brain metastasis | Q37529191 | ||
| Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo | Q37708563 | ||
| Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential | Q38339062 | ||
| Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells | Q39206159 | ||
| The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer | Q39286062 | ||
| Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression | Q39497051 | ||
| Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells | Q39834964 | ||
| Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers | Q42808469 | ||
| Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias | Q44561705 | ||
| Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells | Q46137091 | ||
| Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. | Q46931943 | ||
| MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. | Q50994627 | ||
| Cancer genomics: from discovery science to personalized medicine | Q63018119 | ||
| Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies | Q84510798 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 18171-18182 | |
| P577 | publication date | 2016-02-24 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor | |
| P478 | volume | 7 |
| Q47761894 | An ensemble predictive modeling framework for breast cancer classification |
| Q41085328 | Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. |
| Q50123858 | Challenges in validating candidate therapeutic targets in cancer. |
| Q47105057 | Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types |
| Q42362706 | DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma |
| Q36289944 | Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant |
| Q41338135 | Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. |
| Q50043890 | Identification of potential therapeutic targets in prostate cancer through a cross-species approach. |
| Q91846035 | Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway |
| Q89082194 | Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia |
| Q49187608 | MELK is a novel therapeutic target in high-risk neuroblastoma |
| Q92501934 | MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway |
| Q38648606 | MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. |
| Q91329661 | Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma |
| Q49869942 | Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma |
| Q92465189 | Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1 |
| Q92060222 | Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells |
| Q47345032 | The target landscape of clinical kinase drugs |
| Q41709133 | p53-independent p21 induction by MELK inhibition |
Search more.